Celltrion Decides on Additional 100 Billion KRW Share Buyback

Six Share Buybacks This Year Totaling 550 Billion KRW

Celltrion announced on May 20 that its board of directors has decided to conduct an additional share buyback worth approximately 100 billion KRW. The company plans to purchase 649,351 shares. The buyback will be carried out through on-market purchases starting from May 21.

Celltrion has already carried out six share buybacks this year alone. The cumulative value of this year's buybacks has reached approximately 550 billion KRW, surpassing last year's total of about 436 billion KRW. In addition, recent decisions by Celltrion Group Chairman Seo Jungjin, the holding company Celltrion Holdings, and the group affiliate Celltrion Skincure to each acquire shares worth 50 billion KRW, 100 billion KRW, and 50 billion KRW respectively, demonstrate a commitment to responsible management.

Celltrion employees are also participating in the employee stock ownership plan, with the current scale of the plan amounting to about 40 billion KRW. The combined total of shares purchased by the company, major shareholders, and employees in the market amounts to approximately 800 billion KRW.

Celltrion is not only actively buying back its own shares but is also committed to share cancellation. Since January of this year, the total value of shares either already cancelled or scheduled for cancellation amounts to about 900 billion KRW.

The company stated that it will continue to implement shareholder-friendly policies, such as additional share buybacks and cancellations both domestically and internationally. Another decision on additional share cancellations is expected to be made within the year.

In addition to returning value to shareholders, Celltrion is also working to enhance its corporate value. The company achieved its goal of establishing an 11-product biosimilar portfolio by 2025 ahead of schedule last year, and is accelerating biosimilar approvals and portfolio expansion. In particular, Celltrion plans to actively pursue the development of new drug candidates, including entering the global clinical trial process for next-generation antibody-drug conjugate (ADC) new drugs this year.

A Celltrion representative stated, "Amid growing uncertainty, we have determined that our corporate value is undervalued, which is why we are proceeding with an additional share buyback to further enhance shareholder value. Celltrion will continue to make every effort to improve corporate value, return profits to shareholders, and achieve mutual growth."